News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
535,177 Results
Type
Article (14563)
Company Profile (168)
Press Release (520445)
Multimedia
Podcasts (33)
Webinars (10)
Section
Business (181770)
Career Advice (376)
Deals (27953)
Drug Delivery (20)
Drug Development (62309)
Employer Resources (22)
FDA (11259)
Job Trends (9938)
News (263664)
Policy (20151)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (2)
Academia (749)
Accelerated approval (34)
ADA (21)
Adcomms (17)
Allergies (96)
Alliances (37831)
ALS (124)
Alzheimer's disease (1041)
Antibody-drug conjugate (ADC) (485)
Approvals (11879)
Artificial intelligence (460)
ASCO (337)
Autoimmune disease (244)
Automation (32)
Bankruptcy (281)
Best Places to Work (8105)
BIO (53)
BIOSECURE Act (2)
Biosimilars (165)
Biotechnology (113)
Bladder cancer (195)
Brain cancer (66)
Breast cancer (748)
Cancer (5784)
Cardiovascular disease (238)
Career advice (315)
Career pathing (6)
CAR-T (261)
CDC (5)
Celiac Disease (1)
Cell therapy (665)
Cervical cancer (48)
Clinical research (56230)
Collaboration (1660)
Company closure (2)
Compensation (1426)
Complete response letters (48)
COVID-19 (952)
CRISPR (74)
C-suite (914)
Cystic fibrosis (86)
Data (6766)
Decentralized trials (1)
Denatured (8)
Depression (107)
Dermatology (66)
Diabetes (350)
Diagnostics (4864)
Digital health (39)
Diversity (3)
Diversity, equity & inclusion (8)
Drug discovery (228)
Drug pricing (32)
Drug shortages (3)
Duchenne muscular dystrophy (186)
Earnings (76433)
Editorial (20)
Employer branding (3)
Employer resources (23)
Events (96488)
Executive appointments (838)
FDA (14259)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (17)
Frontotemporal dementia (23)
Funding (1129)
Gene editing (148)
Generative AI (30)
Gene therapy (379)
GLP-1 (387)
Government (1304)
Grass and pollen (2)
Guidances (313)
Healthcare (11194)
Hematology (148)
HIV (58)
Huntington's disease (23)
IgA nephropathy (70)
Immunology and inflammation (149)
Immuno-oncology (119)
Indications (191)
Infectious disease (1165)
Inflammatory bowel disease (147)
Inflation Reduction Act (6)
Influenza (87)
Intellectual property (267)
Interviews (52)
IPO (13323)
IRA (10)
Job creations (2238)
Job search strategy (291)
JPM (27)
Kidney cancer (24)
Labor market (10)
Layoffs (188)
Leadership (9)
Legal (5398)
Liver cancer (77)
Longevity (16)
Lung cancer (815)
Lymphoma (384)
Machine learning (39)
Management (4)
Manufacturing (628)
Marketing (6)
MASH (126)
Medical device (8992)
Medtech (9117)
Mergers & acquisitions (15710)
Metabolic disorders (776)
mRNA (128)
Multiple sclerosis (115)
NASH (5)
Neurodegenerative disease (238)
Neuropsychiatric disorders (46)
Neuroscience (1960)
NextGen: Class of 2026 (3694)
Non-profit (1283)
Now hiring (26)
Obesity (277)
Opinion (54)
Ovarian cancer (231)
Pain (177)
Pancreatic cancer (331)
Parkinson's disease (209)
Partnered (11)
Patents (520)
Patient recruitment (584)
Peanut (31)
People (45843)
Pharmaceutical (38)
Pharmacy benefit managers (9)
Phase 1 (18424)
Phase 2 (24739)
Phase 3 (17551)
Pipeline (7826)
Policy (66)
Postmarket research (1812)
Preclinical (7524)
Press Release (35)
Prostate cancer (301)
Psychedelics (11)
Radiopharmaceuticals (313)
Rare diseases (666)
Real estate (3465)
Recruiting (10)
Regulatory (17150)
Reports (19)
Research institute (1158)
Resumes & cover letters (52)
Rett syndrome (39)
RNA editing (7)
RSV (55)
Schizophrenia (113)
Series A (200)
Series B (138)
Service/supplier (5)
Sickle cell disease (85)
Special edition (5)
Spinal muscular atrophy (91)
Sponsored (12)
Startups (2480)
State (1)
Stomach cancer (14)
Supply chain (57)
Tariffs (8)
The Weekly (24)
Vaccines (437)
Venture capital (56)
Weight loss (98)
Women's health (81)
Date
Today (74)
Last 7 days (316)
Last 30 days (1380)
Last 365 days (22706)
2026 (12679)
2025 (22684)
2024 (26549)
2023 (30396)
2022 (39046)
2021 (41616)
2020 (37497)
2019 (27355)
2018 (20466)
2017 (22037)
2016 (20889)
2015 (26904)
2014 (23410)
2013 (19471)
2012 (21458)
2011 (21720)
2010 (21323)
Location
Africa (291)
Alabama (84)
Alaska (3)
Arizona (299)
Arkansas (13)
Asia (24533)
Australia (3243)
California (12303)
Canada (3322)
China (1020)
Colorado (490)
Connecticut (422)
Delaware (391)
Europe (40283)
Florida (1819)
Georgia (373)
Hawaii (2)
Idaho (49)
Illinois (863)
India (61)
Indiana (400)
Iowa (15)
Japan (468)
Kansas (107)
Kentucky (38)
Louisiana (26)
Maine (25)
Maryland (1306)
Massachusetts (8654)
Michigan (306)
Minnesota (588)
Mississippi (4)
Missouri (85)
Montana (24)
Nebraska (11)
Nevada (114)
New Hampshire (65)
New Jersey (2856)
New Mexico (14)
New York (2971)
North Carolina (1343)
North Dakota (4)
Northern California (6152)
Ohio (286)
Oklahoma (14)
Oregon (18)
Pennsylvania (2436)
Puerto Rico (25)
Rhode Island (31)
South America (473)
South Carolina (77)
South Dakota (1)
Southern California (5062)
Tennessee (142)
Texas (2017)
United States (41279)
Utah (357)
Vermont (1)
Virginia (168)
Washington D.C. (46)
Washington State (944)
West Virginia (1)
Wisconsin (94)
535,177 Results for "epivax oncology inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SV Health Investors Acquires EpiVax
April 3, 2026
·
3 min read
Press Releases
EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide
December 9, 2025
·
2 min read
Press Releases
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
July 21, 2026
·
3 min read
Press Releases
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
May 28, 2025
·
3 min read
Press Releases
AVEO Oncology Announces Succession Plan
June 30, 2026
·
6 min read
Press Releases
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
February 28, 2025
·
3 min read
Drug Development
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai’s robust biologics pipeline.
December 20, 2023
·
2 min read
Press Releases
Biovica Expands Japanese Patent Protection in Immuno-Oncology
July 16, 2026
·
2 min read
Drug Development
Is Revolution ‘the next oncology titan’? Truist analysts make the case
A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology company,” and projects an approval in second-line disease by the end of the third quarter.
May 18, 2026
·
3 min read
·
Heather McKenzie
Press Releases
Cardiff Oncology Announces $10 Million Registered Direct Offering
July 15, 2026
·
6 min read
1 of 53,518
Next
